)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Philogen (PHIL) investor relations material
Philogen Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary26 Sep, 2025
Executive summary
Announced major licensing agreements with RayzeBio (BMS) and Racebio for OncoACP3/OncoCP3, each with $350 million upfront and up to $1 billion in milestones and royalties, significantly strengthening financial resources.
Focused on advancing late-stage clinical programs, especially Nidlegy and Fibromun, and expanding the pipeline with new trials and molecules, supported by a vertically integrated R&D and manufacturing model.
Revenues from contracts with customers rose to €5.5 million, with total revenues reaching €8.7 million, up €7 million year-over-year, driven by clinical trial progress and product sales.
Expanded operations with new clinical offices in Milan, facility upgrades in Monteriggioni and Zurich, and increased research and clinical teams.
Voluntary withdrawal of Nidlegy EMA application to collect additional CMC and clinical data, with resubmission planned.
Financial highlights
Cash and cash equivalents at the end of H1 2025 were €100 million, with liquidity exceeding €350 million after major licensing inflows.
Total revenues for H1 2025: €8.7 million, up €7 million year-over-year, driven by contract manufacturing, licensing, and product sales.
EBITDA: -€13.9 million (improved from -€15.2 million in H1 2024); EBIT: -€15.8 million; net loss: €14.9 million (vs. €15.5 million in H1 2024).
Net financial position: €88.5 million surplus, with €100 million in cash and €88.8 million in liquid financial assets.
Operating costs increased 33% year-over-year, mainly due to higher R&D, clinical trial, and personnel expenses.
Outlook and guidance
Plans to invest new resources in late-stage products and launch additional global trials in non-melanoma skin cancers.
Regulatory resubmission for Nidlegy planned for mid-2026, with ongoing dialogue with authorities and US Phase III two-thirds enrolled.
Anticipates communicating first-line soft tissue sarcoma trial results and progressing glioblastoma trials in coming months.
Multiple Phase I clinical trials for new drug candidates planned over the next 24 months.
Continued collaborations with Sun Pharma, Pfizer, Janssen, Bracco, MSD, and RayzeBio.
RayzeBio payment: future R&D priorities?
Nidlegy™ EU/US regulatory strategy?
OncoCAIX direct Phase III rationale?
ONCOC9: What is the Phase III launch timeline?
Nidlegy EMA resubmission: Next key steps?
Nidlegy US market strategy post-RayzeBio deal?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Philogen earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Philogen S.p.A. is an Italy-based biotechnology company focused on the research and development of targeted therapies for cancer and other serious diseases. The company specializes in antibody-based and small-molecule therapeutics, leveraging its expertise in tumor-targeting technologies. Philogen develops biologic drugs designed to deliver therapeutic agents directly to diseased tissues while minimizing effects on healthy cells. Its research spans from early discovery to clinical development, with a focus on immunotherapy and vascular targeting. The company is headquartered in Siena, Italy, and its shares are listed on the Borsa Italiana.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage